<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728569</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00138533 / Derm 719</org_study_id>
    <nct_id>NCT03728569</nct_id>
  </id_info>
  <brief_title>Skin Barrier Dysfunction and the Role of Skin Barrier Restoration</brief_title>
  <official_title>Skin Barrier Dysfunction and the Role of Skin Barrier Restoration on Cutaneous and Systemic Inflammation in the Aged Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this exploratory study is to gain an understanding of cutaneous and systemic
      inflammation and how restoration of the skin barrier through the use of moisturizer may
      restore the skin barrier function and reduce systemic inflammation in elderly humans compared
      to the young. The exploratory study will consist of three visits per subject. Subjects will
      be instructed to apply a moisturizer (Vanicream Moisturizing Skin Cream) over the entire skin
      surface from the neck down twice daily for up to 30 days.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Enrollment and interactions/interventions paused due to COVID-19. Expected to resume in the
    future. This is not a suspension of IRB approval
  </why_stopped>
  <start_date type="Actual">May 16, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Both groups, young and old, will receive the same intervention; therefore, single group study model was chosen.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in skin hydration status in aged and young subjects</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Trans-epidermal water loss (TEWL) will be performed on the upper arm and buttocks at Visits 1 and 2. This instrument will measure the amount of water that is lost through the skin. The change in skin hydration status in each subject will be assessed and compared between groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cutaneous Inflammation</condition>
  <arm_group>
    <arm_group_label>Subjects over the age of 70 yrs receiving Vanicream</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects between 18 and 30 yrs receiving Vanicream</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vanicream Moisturizing Skin Cream</intervention_name>
    <description>Vanicream Moisturizing Skin Cream daily application</description>
    <arm_group_label>Subjects between 18 and 30 yrs receiving Vanicream</arm_group_label>
    <arm_group_label>Subjects over the age of 70 yrs receiving Vanicream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vanicream Cleansing Soap</intervention_name>
    <description>Vanicream Cleansing Soap daily use</description>
    <arm_group_label>Subjects between 18 and 30 yrs receiving Vanicream</arm_group_label>
    <arm_group_label>Subjects over the age of 70 yrs receiving Vanicream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Aged group (&gt;70 years old)

          -  In good general health

          -  Body mass index (BMI) preferably in the healthy range (approximately 25 kg/m2) and no
             greater than 30 kg/m2

          -  Fitzpatrick skin types I-V

          -  Disrupted skin barrier defined as transepidermal water loss (TEWL) &gt;5 g/m2/h on the
             upper arms or &gt;3 g/m2/h on the buttocks

          -  Clinical signs of skin dryness as determined by the investigator.

          -  No disease states or physical conditions that would impair evaluation of the biopsy
             sites

          -  Signed, written and witnessed informed consent form

          -  Willing to comply with study procedures

        Young group (18-30 years old)

          -  Good general health

          -  BMI preferably in the healthy range (approximately 25 kg/m2) and no greater than 30
             kg/m2

          -  Fitzpatrick skin types I-V

          -  Disrupted skin barrier defined as transepidermal water loss (TEWL) &gt;5 g/m2/h on the
             upper arms or &gt;3 g/m2/h on the buttocks

          -  Clinical signs of skin dryness as determined by the investigator

          -  No disease states or physical conditions that would impair evaluation of the biopsy
             sites

          -  Signed, written and witnessed informed consent form

          -  Willing to comply with study procedures

        Exclusion Criteria:

          -  Pregnant or lactating women or women contemplating pregnancy for the duration of the
             protocol (determined by self-report; if subjects are unsure of their pregnancy status,
             they will be excluded).

          -  Frailty as determined by research study nurse

          -  History of inflammatory skin conditions such as psoriasis or atopic dermatitis.

          -  History of uncontrolled inflammatory or autoimmune disease.

          -  History of keloids or any other condition that would complicate wound healing

          -  History of allergic reactions to local lidocaine

          -  Frequent nonsteroidal anti-inflammatory drug (NSAID) use (not including low dose
             aspirin) and unwilling/unable to discontinue NSAIDS for 2 weeks prior to enrollment to
             the end of the study.

          -  Systemic steroids (excluding inhaled steroids for asthma) and unwilling/unable to
             discontinue systemic steroids for 3 weeks prior to enrollment to the end of the study.

          -  Topical corticosteroid use within 2 weeks of enrollment.

          -  Topical immunomodulation use such as calcineurin inhibitors within 2 weeks of
             enrollment

          -  Other anti-inflammatory or immunodulatory medications (immunosuppression)

          -  Received an experimental drug or used an experimental device 30 days prior to
             admission to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Fisher, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ghadially R, Brown BE, Sequeira-Martin SM, Feingold KR, Elias PM. The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J Clin Invest. 1995 May;95(5):2281-90.</citation>
    <PMID>7738193</PMID>
  </reference>
  <reference>
    <citation>White-Chu EF, Reddy M. Dry skin in the elderly: complexities of a common problem. Clin Dermatol. 2011 Jan-Feb;29(1):37-42. doi: 10.1016/j.clindermatol.2010.07.005. Review.</citation>
    <PMID>21146730</PMID>
  </reference>
  <reference>
    <citation>Kim HO, Kim HS, Youn JC, Shin EC, Park S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med. 2011 Jul 20;9:113. doi: 10.1186/1479-5876-9-113.</citation>
    <PMID>21774806</PMID>
  </reference>
  <reference>
    <citation>Mariani E, Cattini L, Neri S, Malavolta M, Mocchegiani E, Ravaglia G, Facchini A. Simultaneous evaluation of circulating chemokine and cytokine profiles in elderly subjects by multiplex technology: relationship with zinc status. Biogerontology. 2006 Oct-Dec;7(5-6):449-59.</citation>
    <PMID>16967203</PMID>
  </reference>
  <reference>
    <citation>Surmi BK, Hasty AH. Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol. 2008;3(5):545-556.</citation>
    <PMID>18978945</PMID>
  </reference>
  <reference>
    <citation>Katoh N, Hirano S, Kishimoto S, Yasuno H. Acute cutaneous barrier perturbation induces maturation of Langerhans' cells in hairless mice. Acta Derm Venereol. 1997 Sep;77(5):365-9.</citation>
    <PMID>9298129</PMID>
  </reference>
  <reference>
    <citation>Lin TK, Man MQ, Santiago JL, Park K, Roelandt T, Oda Y, Hupe M, Crumrine D, Lee HJ, Gschwandtner M, Thyssen JP, Trullas C, Tschachler E, Feingold KR, Elias PM. Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J Invest Dermatol. 2013 Feb;133(2):469-78. doi: 10.1038/jid.2012.335. Epub 2012 Sep 27.</citation>
    <PMID>23014339</PMID>
  </reference>
  <reference>
    <citation>Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol. 1997 Aug;109(2):175-82.</citation>
    <PMID>9242504</PMID>
  </reference>
  <reference>
    <citation>Onoue A, Kabashima K, Kobayashi M, Mori T, Tokura Y. Induction of eosinophil- and Th2-attracting epidermal chemokines and cutaneous late-phase reaction in tape-stripped skin. Exp Dermatol. 2009 Dec;18(12):1036-43. doi: 10.1111/j.1600-0625.2009.00899.x.</citation>
    <PMID>19558500</PMID>
  </reference>
  <reference>
    <citation>Proksch E, Brasch J, Sterry W. Integrity of the permeability barrier regulates epidermal Langerhans cell density. Br J Dermatol. 1996 Apr;134(4):630-8.</citation>
    <PMID>8733362</PMID>
  </reference>
  <reference>
    <citation>Tsai JC, Feingold KR, Crumrine D, Wood LC, Grunfeld C, Elias PM. Permeability barrier disruption alters the localization and expression of TNF alpha/protein in the epidermis. Arch Dermatol Res. 1994;286(5):242-8.</citation>
    <PMID>8060154</PMID>
  </reference>
  <reference>
    <citation>Wood LC, Stalder AK, Liou A, Campbell IL, Grunfeld C, Elias PM, Feingold KR. Barrier disruption increases gene expression of cytokines and the 55 kD TNF receptor in murine skin. Exp Dermatol. 1997 Apr;6(2):98-104.</citation>
    <PMID>9209892</PMID>
  </reference>
  <reference>
    <citation>Hu L, Mauro TM, Dang E, Man G, Zhang J, Lee D, Wang G, Feingold KR, Elias PM, Man MQ. Epidermal Dysfunction Leads to an Age-Associated Increase in Levels of Serum Inflammatory Cytokines. J Invest Dermatol. 2017 Jun;137(6):1277-1285. doi: 10.1016/j.jid.2017.01.007. Epub 2017 Jan 20.</citation>
    <PMID>28115059</PMID>
  </reference>
  <reference>
    <citation>Jiang YJ, Lu B, Crumrine D, Man MQ, Elias PM, Feingold KR. IL-1alpha accelerates stratum corneum formation and improves permeability barrier homeostasis during murine fetal development. J Dermatol Sci. 2009 May;54(2):88-98. doi: 10.1016/j.jdermsci.2009.01.001. Epub 2009 Feb 11.</citation>
    <PMID>19216058</PMID>
  </reference>
  <reference>
    <citation>Jung YJ, Jung M, Kim M, Hong SP, Choi EH. IL-1α stimulation restores epidermal permeability and antimicrobial barriers compromised by topical tacrolimus. J Invest Dermatol. 2011 Mar;131(3):698-705. doi: 10.1038/jid.2010.344. Epub 2010 Nov 25.</citation>
    <PMID>21107352</PMID>
  </reference>
  <reference>
    <citation>Jiang YJ, Lu B, Crumrine D, Elias PM, Feingold KR. IL-6 stimulates but is not essential for stratum corneum formation and permeability barrier development during gestation. Exp Dermatol. 2010 Aug;19(8):e31-6. doi: 10.1111/j.1600-0625.2009.00968.x.</citation>
    <PMID>19758319</PMID>
  </reference>
  <reference>
    <citation>Upragarin N, Landman WJ, Gaastra W, Gruys E. Extrahepatic production of acute phase serum amyloid A. Histol Histopathol. 2005 Oct;20(4):1295-307. doi: 10.14670/HH-20.1295. Review.</citation>
    <PMID>16136510</PMID>
  </reference>
  <reference>
    <citation>Constantin MM, Poenaru E, Poenaru C, Constantin T. Skin Hydration Assessment through Modern Non-Invasive Bioengineering Technologies. Maedica (Buchar). 2014 Mar;9(1):33-8.</citation>
    <PMID>25553123</PMID>
  </reference>
  <reference>
    <citation>Mundelein M, Valentin B, Chabicovsky R, et al. Transepidermal water loss (TEWL) measurements with two novel sensors based on different sensing principles. Sensors and Actuators A Physical 2007;142(1): DOI 10.1016/j.sna.2007.04.012</citation>
  </reference>
  <reference>
    <citation>Pinnagoda J, Tupker RA, Agner T, Serup J. Guidelines for transepidermal water loss (TEWL) measurement. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis. 1990 Mar;22(3):164-78.</citation>
    <PMID>2335090</PMID>
  </reference>
  <reference>
    <citation>Kottner J, Lichterfeld A, Blume-Peytavi U. Transepidermal water loss in young and aged healthy humans: a systematic review and meta-analysis. Arch Dermatol Res. 2013 May;305(4):315-23. doi: 10.1007/s00403-012-1313-6. Epub 2013 Jan 23. Review.</citation>
    <PMID>23341028</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Gary Fisher</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

